Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer.
David J. Sher , Mary Jo Fidler , Roy B. Tishler , Kerstin Stenson
International Journal of Radiation Oncology Biology Physics 94 ( 3) 512 -522
25
2016
Relationship between radiation therapy dose and outcome in patients treated with neoadjuvant chemoradiation therapy and surgery for stage IIIA non-small cell lung cancer: A population-based, comparative effectiveness analysis
David J. Sher , Mary Jo Fidler , Christopher W. Seder , Michael J. Liptay
International Journal of Radiation Oncology Biology Physics 92 ( 2) 307 -316
13
2015
Phase II trial of CDX-3379 and cetuximab in recurrent/metastatic, HPV-negative, cetuximab-resistant head and neck cancer
Julie E Bauman , Ricklie Julian , Nabil F Saba , Trisha M Wise-Draper
Cancers 14 ( 10) 2355
2
2022
Travel Grants have been awarded by the Chicago Multidisciplinary Symposium in Thoracic Oncology to the following recipients on a competitive basis from among the accetped abstracts
Xianglin Yuan , Rom Leidner , Xiong Wei , Bradford Hoppe
Journal of Thoracic Oncology 3 ( 11 Supplement 4)
2008
Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy
Shalini Garg , Benjamin T Gielda , Krystyna Kiel , Julius V Turian
Practical radiation oncology 4 ( 5) 342 -348
33
2014
Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer
Narjust Florez , Lauren Kiel , Kelly Meza , Zihan Wei
Cancer 130 ( 3) 375 -384
1
2024
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
Laura Burns , Chih-Yuan Hsu , Jennifer G Whisenant , Melina E Marmarelis
Lung Cancer 186 107423 -107423
2023
A nationwide analysis of salvage surgery for laryngeal cancer in the elderly
Richard A Raad , Katie Holland , Ethan M Ritz , Bobby A Tajudeen
Head & Neck 45 ( 11) 2915 -2924
2023
Unusual vasovagal-type autonomic dysfunction secondary to immune checkpoint inhibitor therapy
Kelsey Danley , Mary Jo Fidler , Aliyah Sadaf , Tochukwu M Okwuosa
BMJ Case Reports CP 16 ( 2) e251034 -e251034
2023
Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies
KEVIN King , RYAN Rauch , SOUMYAJIT Roy , OLEG Menyok
Anticancer Research 42 ( 11) 5449 -5455
2022
Comprehensive profiling of immune regulatory molecules in baseline sera from advanced stage NSCLC patients receiving anti-PD-1 and anti-PD-L1 immunotherapy: A prognostic potential
Imad Tarhoni , Hita Moudgalya , Sanjib Basu , Wen_Rong Lie
Cancer Research 81 ( 13_Supplement) 1621 -1621
2021
Novel Autoantibodies Biomarkers Panel Test to Prognosticate Clinical Outcomes in Advanced-stage NSCLC Patients Receiving Anti PD-1/-L1 Immunotherapy
Imad A Tarhoni , Cristina Fhied , Hita Moudgalya , Muhammad Abdur Raafey
AMERICAN JOURNAL OF PATHOLOGY 190 ( 12) S20 -S20
2020
Autoantibodies: A promising prognostic tool for immunotherapy response in advanced non-small cell lung cancer
Imad Tarhoni , Cristina Fhied , Melissa Pergande , Revathi Kollipara
Cancer Research 79 ( 13_Supplement) 426 -426
2019
Prognostic value of soluble and cell surface immune-checkpoint molecules in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1/-L1 immunotherapy
Imad Tarhoni , Mary Jo Fidler , Ibtihaj Fughhi , Connor Wakefield
Cancer Research 79 ( 13_Supplement) 404 -404
2019
PREDICTORS OF TRIMODALITY THERAPY USE AND OVERALL SURVIVAL IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NATIONAL CANCER DATABASE
Mary Jo Fidler , Micheal Liptay , Philip Bonomi , David Sher
JOURNAL OF THORACIC ONCOLOGY 8 S137 -S138
2013
THYROID TRANSCRIPTION FACTOR (TTF-1) NEGATIVE LUNG ADENOCARCINOMAS WILL BE WILD TYPE FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS.
Mary Jo Fidler , Neeta Somaiah , Elizabeth Garrett-Mayer , Xu Huang
JOURNAL OF THORACIC ONCOLOGY 8 S666 -S666
2013
PROLONGATION OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER BEFORE AND AFTER FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF ACTIVE SECOND LINE AGENTS: A META-ANALYSIS
Mary Jo Fidler , Sanjib Basu , Marta Batus , Philip Bonomi
JOURNAL OF THORACIC ONCOLOGY 8 S580 -S580
2013
CIRCULATING BIOMARKERS MAY HELP GUIDE SELECTION OF ERLOTINIB VERSUS CHEMOTHERAPY IN PRETREATED ADVANCED NSCLC PATIENTS.
Jeffrey A Borgia , Marta Batus , Mary Jo Fidler , JA Gangaram
JOURNAL OF THORACIC ONCOLOGY 8 S1097 -S1098
2013
DEVELOPMENT OF A SERUM BIOMARKER PANEL PREDICTING CLINICAL OUTCOME OF CHEMOTHERAPY WITH PEMETREXED IN PATIENTS WITH NSCLC
Jeffrey A Borgia , Marta Batus , Mary Jo Fidler , Shruthi Melinamani
JOURNAL OF THORACIC ONCOLOGY 8 S499 -S500
2013
WEIGHT GAIN DURING FIRST-LINE CHEMOTHERAPY FOR LOCALLY ADVANCED AND METASTATIC NON-SMALL-CELL LUNG CANCER IS ASSOCIATED WITH IMPROVED SURVIVAL
Iva Ferreira , Mohammed Azeem , Sanjib Basu , Shannon Sims
JOURNAL OF THORACIC ONCOLOGY 8 S1178 -S1179
2013